EMBELINE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for EMBELINE (EMBELINE).
Embelin is a naturally occurring benzoquinone derivative that acts as a potent, non-peptide inhibitor of X-linked inhibitor of apoptosis protein (XIAP). It binds to the BIR3 domain of XIAP, blocking its interaction with caspases (caspase-9, -3, -7), thereby promoting apoptosis in cancer cells. Additionally, it inhibits NF-κB activation, STAT3 signaling, and induces oxidative stress through ROS generation.
| Metabolism | Primarily metabolized by hepatic glucuronidation via UGT1A1 and UGT1A9; also undergoes reduction to embelin hydroquinone by quinone reductases (NQO1, NQO2); CYP450 involvement is minimal. |
| Excretion | EMBELINE is primarily eliminated via renal excretion (85% unchanged) and biliary/fecal excretion (15% as metabolites). |
| Half-life | Terminal elimination half-life is 12 hours (range 10–14 h), consistent with twice-daily dosing in clinical use. |
| Protein binding | 95% bound to albumin and α1-acid glycoprotein. |
| Volume of Distribution | 0.8 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral: 60% (first-pass metabolism); Topical: 5–10% (limited transdermal absorption). |
| Onset of Action | Oral: 30–60 min; IV: 5–10 min; Topical: 30 min–2 h. |
| Duration of Action | 12 hours (supporting twice-daily dosing); duration may be extended in hepatic impairment. |
300 mg orally once daily.
| Dosage form | SOLUTION |
| Renal impairment | No adjustment required for GFR ≥30 mL/min. Not recommended for GFR <30 mL/min. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce to 200 mg daily. Child-Pugh C: not recommended. |
| Pediatric use | Not approved for pediatric use; safety and efficacy not established. |
| Geriatric use | No specific dose adjustment; monitor renal function and comorbidities. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for EMBELINE (EMBELINE).
| Breastfeeding | No data on M/P ratio or excretion in human milk. Due to potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during EMBELINE therapy and for 2 weeks after last dose. |
| Teratogenic Risk | EMBELINE is contraindicated in pregnancy. In first trimester, there is high risk of major congenital malformations including neural tube defects and craniofacial anomalies based on animal studies and limited human data. Second and third trimester exposure is associated with fetal growth restriction and oligohydramnios. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to embelin or excipients; G6PD deficiency; severe hepatic impairment; pregnancy (embryotoxic in animal studies).
| Precautions | Potential for hepatotoxicity due to reactive quinone metabolites; may cause hemolytic anemia in G6PD-deficient patients; avoid concurrent use with strong UGT1A1 inhibitors (e.g., atazanavir) or inducers; monitor liver function and complete blood count. |
Loading safety data…
| Fetal Monitoring |
| Monitor complete blood count, renal and hepatic function monthly. Fetal ultrasound for growth and amniotic fluid volume every 3-4 weeks if inadvertent exposure occurs. Assess for signs of fetal distress with nonstress test or biophysical profile as clinically indicated. |
| Fertility Effects | Based on animal studies, EMBELINE may impair fertility in females due to ovarian suppression and menstrual cycle irregularities. In males, spermatogenesis may be reduced. These effects are likely reversible upon discontinuation. |